# Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

> **NCT04969731** · PHASE3 · RECRUITING · sponsor: **GC Cell Corporation** · enrollment: 408 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Immuncell-LC
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04969731
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-07
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969731, "Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04969731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*